BridgeBio Pharma Target Price

Where could BBIO trade next? Consensus target price: $110.

Get informed when a big investor buys or sells

+ Follow

Share Price

$68.56

Average Target Price

$110.17

60.7% upside

12 analysts in the last 4 months

High: $156 | Low: $87

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-10-21	Morgan Stanley	$87	26.9% upside
2026-10-19	Piper Sandler	$120	75% upside
2026-10-15	UBS	$92	34.2% upside
2026-10-07	Barclays	$156	127.5% upside
2026-09-01	Mizuho Securities	$110	60.4% upside
2026-08-12	Canaccord Genuity	$106	54.6% upside
2026-08-12	Truist FinancialDanielle Brill	$107	56.1% upside
2026-08-11	Wells FargoDerek Archila	$102	48.8% upside
2026-08-11	Piper Sandler	$115	67.7% upside
2026-08-11	Cantor FitzgeraldJosh Schimmer	$110	60.4% upside
2026-08-11	Morgan StanleySean Laaman	$97	41.5% upside
2026-07-13	H.C. Wainwright	$120	75% upside
2026-06-16	Mizuho SecuritiesSalim Syed	$96	40% upside
2026-06-03	Canaccord Genuity	$104	51.7% upside
2026-05-28	Morgan Stanley	$98	42.9% upside
2026-05-11	H.C. Wainwright	$110	60.4% upside
2026-05-08	Bernstein	$114	66.3% upside
2026-05-08	Evercore ISI	$130	89.6% upside
2026-04-29	Truist FinancialDanielle Brill	$102	48.8% upside
2026-04-08	RBC CapitalLuca Issi	$100	45.9% upside
2026-03-12	Leerink PartnersMani Foroohar	$98	42.9% upside
2026-02-25	Truist FinancialDanielle Brill	$95	38.6% upside
2026-02-17	H.C. WainwrightRaghuram Selvaraju	$100	45.9% upside
2026-02-13	OppenheimerTrevor Allred	$83	21.1% upside
2026-02-13	Tudor PickeringWilliam Pickering	$100	45.9% upside
2026-02-12	JefferiesAndrew Tsai	$100	45.9% upside
2026-02-12	Raymond JamesMartin Auster	$89	29.8% upside
2026-01-27	Barclays	$157	129% upside
2026-01-20	Wells FargoTiago Fauth	$88	28.4% upside
2026-01-08	Truist Financial	$86	25.4% upside
2026-01-06	Morgan Stanley	$96	40% upside
2025-12-15	Leerink Partners	$86	25.4% upside
2025-12-11	Bernstein	$94	37.1% upside
2025-10-30	Truist Financial	$80	16.7% upside
2025-10-30	Oppenheimer	$81	18.1% upside
2025-10-30	Piper Sandler	$98	42.9% upside
2025-10-30	Goldman SachsPaul Choi	$100	45.9% upside
2025-10-29	H.C. Wainwright	$90	31.3% upside
2025-10-28	H.C. Wainwright	$80	16.7% upside
2025-10-27	Raymond James	$69	0.6% upside
2025-10-27	Leerink PartnersMani Foroohar	$68	0.8% downside
2025-08-29	H.C. WainwrightRaghuram Selvaraju	$70	2.1% upside
2025-04-30	UBSEliana Merle	$72	5% upside
2024-10-24	CitigroupDavid Lebowitz	$45	34.4% downside
2024-10-17	Leerink PartnersMani Foroohar	$46	32.9% downside
2024-09-11	Piper SandlerBiren Amin	$46	32.9% downside
2024-09-03	Mizuho SecuritiesSalim Syed	$53	22.7% downside
2024-06-24	Raymond JamesDanielle Brill	$46	32.9% downside
2024-06-05	BMO CapitalKostas Biliouris	$37	46% downside
2024-06-05	Wells FargoTiago Fauth	$58	15.4% downside

BridgeBio Pharma (BBIO) FAQ

BridgeBio Pharma posts a target price of $110. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $110 for BBIO means covering analysts, on average, see the stock 60.7% upside of $68.56 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for BBIO's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; BridgeBio Pharma's other metric pages and overview cover the third.

Judging BridgeBio Pharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $110 here, then scan peer and history charts to see if the gap is persistent.